Summary. In order to study the heterogeneity of Type 2 (noninsulin-dependent) diabetes, we determined HLA antigens and measured B-cell function as C-peptide response to intravenous glucagon in 217 patients with onset of non-ketotic diabetes after the age of 40 years. Their HLA frequencies were compared with those of Type 1 (insulin-dependent) diabetic patients and of healthy blood donors. The Type 1 diabetic patients showed a typical HLA pattern, with increased frequencies of B15, DR3, DR4, B8/B15 and DR3/DR4 and decreased frequencies of B7 and DR2. The Type 2 diabetic patients could be distinguished from blood donors by increased frequencies of Cw4, DR4, DR5 and DR3/DR4, and from Type 1 diabetic patients by increased frequencies of B7, DR2, DR5 and decreased frequency of A9, Bw22 and DR4. Age at onset and body mass index were unrelated to HLA antigens, but the Type 2 diabetic patients with HLA-Cw4, DR5 and DR6 showed a strong family history for Type 2 diabetes. Type2 diabetic patients with HLA-B8, DR4, B8/B15 and DR3/DR4 showed significantly lower C-peptide concentrations (p < 0.05) than patients without these HLA antigens. In contrast, patients with DR5 and DRw8 presented with high Cpeptide levels. Twelve patients who were positive for both DR3 and DR4 and 23 patients who were DR3/DR4 negative were followed with repeated C-peptide determinations during a period of three years. The C-peptide concentrations of the DR3/DR4 positive patients decreased during this period, whereas there was no change in C-peptide levels in the DR3/DR4 negative patients. In conclusion, B-cell function measured as C-peptide response to glucagon correlates with HLA antigens in patients with onset of diabetes after age 40. Impaired B-cell function seems to be associated with Type 1 diabetes-related HLA-antigens, whereas the presence of DR5 was associated with preserved B-cell function and a strong heredity for Type 2 diabetes. The results thus support the concept of heterogeneity in Type 2 diabetes. Admixture of patients with latent Type 1 diabetes can at least partially account for this heterogeneity.
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Over the past several years, much information has accumulated which indicates that Type 2 diabetes is a heterogeneous disorder [1] [2] [3] . Probably the most critical issue is distinguishing patients with Type 1 from those with Type 2 diabetes. The definition of Type 2 diabetes is crude and based on clinical findings which are not exclusive, i.e. absence of ketosis and response to treatment with diet and/or oral antidiabetic agents [1] . However, ketosis can be absent and the patient can respond to treatment with oral antidiabetic agents in the early stages of Type 1 diabetes. Admixture of patients with late onset Type I diabetes within the group of Type 2 diabetes could account for part of the heterogeneity. Therefore, it would be of real clinical value to identify patients with late onset Type I diabetes. Islet cell antibodies are specific but insensitive markers of Type 1 diabetes and are less frequent in patients with late onset of the disease [4] . Genetic susceptibility to Type i diabetes is associated with increased frequency of the HLA antigens DR3, DR4, and the heterozygous form DR3/DR4 and decreased frequency of HLA-DR2 [5] [6] . Until recently [7] Type 2 diabetes was not considered to be associated with any specific HLA antigen(s).
With this knowledge, we anticipated that it might be possible to distinguish a subgroup of patients with Type 2 diabetes who may later develop insulin dependence and thus be considered to have late onset Type 1 diabetes. We also anticipated that these patients would differ from Type 2 diabetic patients in terms of B-cell function. To test this hypothesis we determined HLA antigens and measured B-cell function in 217 patients with onset of non-ketotic diabetes after the age of 40 years. We also compared their frequencies of HLA phenotypes with those of Type 1 diabetic patients and healthy blood donors.
Subjects and methods
Table1. Frequencies of HLA-A and -B antigens in blood donors, Type 1 and Type 2 diabetic patients Two hundred seventeen patients (111 females and 106 males) with on-HLA set of non-ketotic diabetes between the ages of 40 and 70 years were antigen randomly drawn from the register of the Helsinki Diabetic Association and investigated for their B-cell function and HLA antigens. Diagnosis of diabetes had been established in all subjects in accordance n % with the National Diabetes Data Group criteria [1] . Patients with secondary diabetes were excluded from the study. All patients were A1 181 treated with diet and/or oral antidiabetic agents when investigated. A2 486 Eighty-nine patients (41%) were additionally treated with antihyper-A3 400 tensive drugs, and sixty patients (28%) used digitalis because ofcardio-A9 146 vascular disease. None of the subjects showed signs of impaired he-A10 70 patic or renal function or used medication known to influence B-cell All 79 function. The patients were informed of the purpose and [8] . Plasma C-peptide was analyzed by a modification of B27 126 the radioimmunoassay described by Heding [9] . The inter-assay and B35 245 intra-assay variation coefficients were 7 and 5% respectively. All pat-B40 161 ients were typed for HLA-A, B-and Cw antigens; additionally B8/B15 23 121 patients were typed for DR antigens. Ninety C-peptide negative patients with long-standing Type 1 diabetes (mean age 35 + 6 years) and blood donors from the same geographical area served as controls for the HLA determinations. HLA typing was performed by a standard two stage microcytotoxicity method using a total of 120 antisera defining 11 Alocus, 20 B locus and 7 Cw locus specifities. Eight DR specificities were defined using a minimum of 60 antisera [10] .
Twelve consecutive patients with both DR3 and DR4 (5 females HLA and 7 males) with a mean duration of diabetes of 8 _+ 6 years and a mean age of 58 _+ 6 years, and 23 consecutive DR3/DR4 negative patantigen ients (i. e. without the heterozygous form DR3/DR4; 11 females and 12 males) with a mean duration of 7 + 5 years and a mean age of 55 + n % 6 years, were followed with repeated C-peptide determinations during a period of 3 years (Fig. 2) .
Statistical analysis
Values are expressed as means + SD or as means +_ SEM. Statistical analysis was performed by analysis of variance, chi-square test or Fisher's exact probability test by the use of a BMDP computer program [11] . When comparing differences in HLA phenotype frequencies, the obtained p values were corrected for the number of antigens defined in the sample at the locus in question. A p value of < 0.05 was considered statistically significant.
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Results
The frequencies of HLA-A and -B antigens in blood donors, Type 1 and Type 2 diabetic subjects are shown in Table 1 , and those of Cw and DR antigens in Tables 2  and 3 (X 2=14.25; p=0.002), DR4 ()(2=36.88; p= 0.000), DR3/DR4 (X 2 = 27.63 ; p = 0.000) and lower frequencies of B7 (X2=14.54; p=0.004) and DR2 (X~= 22.77; p = 0.000) than blood donors. The Type 2 diabetic patients showed higher frequencies of HLA-Cw4 (X2=12.68; p=0.004), DR4 (X2=9.17; p=0.020), DR5 (X 2 = 18.25; p = 0.000) and DR3/DR4 (X 2 = 7.99; p=0.038) than the blood donors. They differed from Type 1 diabetic patients with respect to lower frequency of HLA-A9 (X~=9.55; p=0.044), DR2 (X2=10.33; Fig. 1 . C-peptide response to glucagon in relation to HLA antigens in patients with onset of non-ketotic diabetes after age 40. The bars represent the difference from the mean of all patients. The number of studied patients with a given HLA antigen is given within brackets.
Patients with B8/B15 and DR3/DR4 were heterozygous for these phenotypes. *p < 0.05; **p < 0.02 vs patients without the HLA-antigen(s) Fig.2 . C-peptide response to glucagon decreased significantly in 12 patients with both DR3 and DR4 during a follow-up period of three years (p < 0.01). In contrast, there was no change in post-glucagon C-peptide concentrations of 23 patients who were negative for both DR3 and DR4 during the same period. *p < 0.01 ; significance of difference from the beginning of the follow-up period. DR3/DR4-(0 ..... 0); DR3/DR4 + ('--') p = 0.012), DR4 (X 2 = 8.32; p = 0.03l) and a tendency to higher frequency of DR5 (X 2 = 7.18; p = 0.056). Age at onset and body mass index were not related to HLA antigens (Table 4) . However, a first degree family history of Type 2 diabetes was more common among patients with the HLA antigens Cw4, DR5 and DRw6 than among patients without these HLA antigens (p < 0.05, p < 0.01 and p < 0.001 respectively). The mean post-glucagon C-pepfide concentration of all patients was 1.0 + 0.04 nmol/1, and that of age-and weight-matched healthy subjects was 1.30_+ 0.08 nmol/1 (n = 34). Patients who were positive for HLA-B8, DR4, DR3/DR4 and B8/B15 showed significantly lower glucagon stimulated C-peptide concentrations than patients without these HLA antigens (p < 0.05) ( Table 4 , Fig. 1 ). In contrast, the HLA antigens DR5 and DRw8 were associated with increased C-peptide response to glucagon (p < 0.05). The C-peptide concentrations of the DR3/DR4 positive patients decreased significantly during the follow-up period (p < 0.01), whereas there was no change of C-peptide concentrations with time in the DR3/DR4 negative patients (Fig. 2) .
Discussion
The Type I diabetic patients in this study showed a typical HLA pattern, with the known increase in HLA-DR3, DR4, DR3/DR4 and decrease in DR2. Indeed, 90% of them had either DR3 or DR4, which is similar to those reported in Danish [12] and British [6] studies. The DR frequencies in the blood donors were similar to those reported in other Caucasian populations [6, 13] ; suggesting that the deviation in HLA antigens seen in the diabetic patients were related to the disease itself. The patients with Type 2 diabetes showed a HLA pattern which partially resembled that of Type I diabetes (increased frequencies of DR4 and DR3/DR4), partially that of the background population (no decrease in the frequency of B7 and DR2). This intermediate position of Type 2 diabetes in terms of HLA antigens can be interpreted in two ways. Firstly, Type 2 diabetes does not differ from the background population with respect to HLA antigens, and the increase in DR4 and DR3/DR4 reflects admixture of patients with late onset of Type I diabetes within the spectrum of Type 2 diabetes. This is supported by the findings of similar frequencies of B7 and DR2 in Type 2 diabetic patients as in blood donors, and the increase in the Type 1-related HLA antigens thus reflects admixture. Secondly, Type 2 diabetes is a heterogeneous disease including several subsets, one of them showing a HLA pattern similar to that seen in Type I diabetes. The concept of heterogeneity is supported by the increased frequency of Cw4 and DR5 in the Type 2 diabetic patients, the frequency of DR5 also being higher than in Type i diabetes. Interestingly, patients with Cw4 and DR5 showed an increased frequency of a first degree family history of Type 2 diabetes, suggesting a strong genetic background in Type 2 diabetic patients with these HLA antigens. To further address the question of admixture or heterogeneity, we analysed B-cell function in the Type 2 diabetic patients in relation to HLA antigens. In the case of admixture, we assumed that patients with Type 1-related HLA antigens would show some degree of impaired Bcell function. This was, in fact, what we observed; patients with B8, DR4 and especially B8/B15 and DR3/DR4 showed decreased C-peptide response to glucagon. Furthermore, the presence of DR3/DR4 predicted a progressive decrease in B-cell function over time. On the other hand, patients with the "Type 2-related" HLA antigen DR5 presented with increased C-peptide response to glucagon. Factors other than impaired B-cell function must be involved in the pathogenesis of diabetes in these patients.
In conclusion, our results indicate a relationship between B-cell function and HLA antigens in patients with onset of non-ketotic diabetes after the age of 40 years. They also support the view that Type 2 diabe-tes is a heterogeneous disease. Admixture of patients with latent Type I diabetes within the group of Type 2 diabetes could partially contribute to this heterogeneity.
